Since its inception, transvenous pacing has been used worldwide in millions of patients.
Continued advancements have yielded smaller, more technically advanced pulse generators
with a multitude of programmable features. Concomitant improvements in lead design
and construction have resulted in smaller caliber and more reliable leads. However,
despite these advances, the inherent risks associated with transvenous pacemaker implantation
have not changed. Because there is no national registry of patients undergoing transvenous
pacemaker implantation, the overall incidence of complications has been difficult
to define. What we do know is use of pacemakers has increased over the years, and
patients now being implanted are older and have more comorbidities.
1
Thus, it is not entirely surprising that a recent retrospective review showed a 10%
complication rate even with de novo single-chamber transvenous pacemaker implantation.
2
Similarly, high complication rates were observed in a prospective registry.
3
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart RhythmAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures.J Am Coll Cardiol. 2012; 60: 1540-1545
- Complications after cardiac implantable electronic device implantation: an analysis of a complete, nationwide cohort in Denmark.Eur Heart J. 2014; 35: 1186-1194
- Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study.Heart Rhythm. 2012; 9: 728-735
- Permanent leadless cardiac pacemaker therapy: a comprehensive review.Circulation. 2017; 135: 1458-1470
- A leadless intracardiac transcatheter pacing system.N Engl J Med. 2016; 374: 533-541
- Leadless pacemaker in the real-world setting: the Micra transcatheter pacing system postapproval registry.Heart Rhythm. 2017; 14: 1375-1379
- Pacemaker or defibrillator surgery without interruption of anticoagulation.N Engl J Med. 2013; 368: 2084-2093
- Extraction of a Micra transcatheter pacing system: first-in-human experience.HeartRhythm Case Rep. 2016; 2: 60-62
- Postmortem histopathological examination of a leadless pacemaker shows partial encapsulation after 19 months.Circ Arrhythm Electrophysiol. 2015; 8: 1293-1295
- Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice.Heart Rhythm. 2015; 12: 305-312
Article info
Publication history
Published online: June 09, 2017
Footnotes
Dr Mittal is a consultant to Medtronic.
Identification
Copyright
© 2017 Heart Rhythm Society. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval RegistryHeart RhythmVol. 14Issue 9
- PreviewFirst-in-man studies of leadless pacemakers have demonstrated high rates of implant success, and safety and efficacy objectives were achieved. Outside of the investigational setting, there are concerns, particularly over cardiac effusion and perforation, device dislodgement, infection, telemetry, and battery issues.
- Full-Text
- Preview
